With the timeline to launch a study in India similar to the one being conducted in Australia significantly longer than AEMD had initially anticipated, the company has decided not to move forward in India at this time. AEMD will continue to focus on the ongoing oncology study in Australia, where it benefits from attractive economic that are expected to help reduce costs, lower risk & accelerate time to market. When appropriate, the company continues pre-clinical research and analysis of the Hemopurifier in areas outside of oncology when expenses associated with these efforts are de minimis. This includes recent research conducted in collaboration with UCSF that led to AEMD's CMO presenting last week on the potential benefits of the Hemopurifier in treating Long COVID & papers on preclinical data showing the Hemopurifier's ability to remove platelet-derived EVs from plasma published in the Transplant Immunology Journal.
